1MahmooclNA, Silver K, Onef K etal. Efficacy and safety of rituximab in pediatric neuromyelitis optica[J]. J Child Neurol, 2011. 26(2),244-247.
2王化冰.视神经脊髓炎王维治.神经病学.第5版.北京:人民卫生出版社,2006.1154.
3Bergamaschi R. Importance of eerebrospinal fluid ex-amination in dif- ferential diagnosis of Devie7S neu-romyelitis optica by multiple sclero- sis. NeurolSci ,2009,24 ( 3 ) :95.
4De--Seze J. Neuromyelitis optica. Arch Nenrol,2007,60 (9) : 1336.
5Wingerchuk DM. Weinshenker BG. Neuromyelitis optica:Clinical pre- dictors of a relapsing course and survival. Neurology ,2009,60 (5) :848-853.
6Bekker J, Metz L. Devicg neuromyelitis optica treated with intravenous gamma globulin(IVIG). Can J Neurol Sci,2008,31:265.
7Bonnan M,Valentino R, Olindo S, et al. Plasma exchange insevere spi- nal attacks associated with neuromyelitis opticaspectrum disorder. Mult Scler, 2009,15:487-492.
8Wingerehuk DM, Hogancamp WF, Op Brien PC, et al. The clinical course of neuromyelitis optica (Devic' s syndrome ) [J]. Neurology,1999,5g: 1307-1114.
9Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum au- toantibody marker of neurornyelitis optica: distinction from multiple sclerosis[J], Lancet, 2004,364 : 2106-2112,.
